Order Entry

Monoclonal antibodies (mAbs)

Optimize your mAbs bioprocessing performance with industry-leading solutions

Monoclonal antibodies (mAbs) production | Avantor

Monoclonal antibodies (mAbs) are at the forefront of the biological products market. They will continue to lead resource investment in the biopharmaceutical industry to help provide innovative therapeutic solutions for immune-oncology and immunotherapy.

Avantor® offers an industry-leading portfolio of upstream, downstream, and drug product bioprocessing solutions. Our solutions help you maintain mAbs quality, activity, and stability throughout the entire process.


Our fully characterized products for upstream processing of mAbs are designed to support cell growth, consistency, and productivity while meeting the required quality and performance parameters. Avantor’s commitment to using an open architecture design of single-use assemblies allows the seamless transfer from process development to pilot scale and final commercial manufacturing.


Our industry-leading Avantor J.T.Baker® brand buffer product line and J.T.Baker® BAKERBOND™ chromatography resins, including the BAKERBOND® PROchievA™ recombinant protein A resin, are trusted for high performance in mAbs manufacturing. We also provide downstream optimization services, including column packing and process development support to streamline your operations.


Avantor offers the highest purity excipients you need to progress from drug substance to final drug product, including adjuvants, stabilizers, preservatives, and bulking agents used in drug product formulation to minimize drug product degradation. We also offer packaging vials and stoppers that meet stringent internal and external quality requirements.


Avantor supports every stage of the mAbs manufacturing process with fluid handling technologies, including single-use components, connectors, and assemblies as well as Masterflex® peristaltic pumps for aseptic fluid handling and storage. Our experts collaborate to design customized solutions that meet your exact process and compliance requirements, utilizing a global supply network for security and convenience.


Maintaining aseptic conditions during the manufacturing or down packing process is part of managing your risk. We offer products from industry-leading manufacturers and support from our teams of specialists who have the technical and industry experience to recommend the best solutions to meet your needs.

How can we help?

Avantor’s solutions, combined with our experience and insights into bioprocessing optimization, can help biopharma manufacturers increase mAb titers, mAb fragments that can be manufactured in other expression systems, multiple target specificity for mAbs, and the development of Antibody-Drug Conjugates (ADCs) that deliver drugs to targeted cancer cells.

Our portfolio includes mission-critical products and services that support every stage of your process, from monoclonal antibodies research to production. We have a global infrastructure that serves more than 225,000 customer locations worldwide. Let us improve your bioproduction efficiencies so you can focus on scientific breakthroughs.


Avantor's hydration solutions

Avantor is the ideal partner to develop innovative, customized, buffer solutions that save you time, resources, and money.

Play video

What Are Monoclonal Antibodies?

Monoclonal antibodies, also called mAbs, are proteins made in a laboratory that act identically to immune system antibodies. These manufactured antibodies come from a single unique parent cell and are exact replicas of antibodies that target one specific antigen. That makes them ideal for targeted monoclonal antibodies immunotherapy.

Among the uses for monoclonal antibodies are the treatment diseases, including:

  • Cancer
  • Autoimmune diseases
  • Asthma
  • Viral infections, such as Ebola and COVID-19

Monoclonal antibodies are used for a variety of diagnostic procedures that include:

  • Lymphoid and myeloid malignancies
  • Tissue typing
  • Enzyme-linked immunosorbent assay
  • Radioimmunoassay
  • Serotyping of microorganisms
  • Immunological intervention with passive antibody
  • Anti-idiotype inhibition
How Do Monoclonal Antibodies Work?

Monoclonal antibodies (mAbs) work in a variety of ways depending on the protein they are targeting. Each mAb mimics one of the body’s natural antibodies and functions as immunotherapy by targeting one particular protein to:

  • Trigger the immune system
  • Help the immune system
  • Block signals or target another aspect of the cell
Future of Monoclonal Antibodies Treatment

Monoclonal antibodies (mAbs) are the largest sector in the biologics market, based on revenues and drug pipelines. The clinical benefit of mAbs has been effective in treating autoimmune diseases and oncology.

Significant investments are now focusing on developing mAbs for the growing field of immuno-oncology or monoclonal antibodies immunotherapy. Efforts include process optimization to increase mAb titers, mAb fragments manufactured in other expression systems, multiple target specificity for mAbs, and the development of Antibody-Drug Conjugates (ADCs) that deliver highly toxic drugs to targeted cancer cells.

Related content

Ready to move forward? Contact us to get started.